The German-British joint venture brings together the expertise and experience of three leading
consulting and pharmaceutical companies to offer comprehensive and innovative solutions for
pharmaceutical industry.
Through a network of international partners and suppliers, Kynelion Pharma Group offers a broad
range of pharmaceutical products for licensing, registration, technology transfer and distribution to
enable its customers to access new products and markets.
"The formation of this joint venture is an important milestone for all three companies," said Dr. John
Medina, CEO of COTECTRA GmbH. "We are excited to combine our strengths and work together to
create innovative solutions that will benefit our clients and patients around the world."
Kynelion Pharma Group will act as a bridge between pharmaceutical companies in Europe and the target regions, facilitating the exchange of technology, expertise, and knowledge to drive pharmaceutical innovation and improve patient outcomes.
"We are proud to be partnering with COTECTRA GmbH and SCHIRMEN PHARMA GmbH," said Manuel
Kirk, CEO of BIO-SYNERGIX INTERNATIONAL Ltd. "This joint venture will enable us to leverage each
other's strengths and resources to supply new and innovative drugs that will have a significant
impact on the pharmaceutical industry in the countries we operate in."
Kynelion Pharma Group will assist companies to navigate complex regulatory environments, establish market access strategies, and identify potential partners for technology transfer and distribution. "Our joint venture aims to provide global solutions for pharmaceutical and biopharmaceutical
companies seeking to expand their business internationally," said Mr. Armand Biwole, the CEO of
SCHIRMEN PHARMACEUTICALS GmbH. "Our joint venture will enable us to combine our expertise
and resources to create new opportunities for growth and development."
The joint venture will be headquartered in Dresden, Germany, with offices in London, Bogota, Mexico City and Rio de Janeiro.
